Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab + lenalidomide + rituximab versus placebo + lenalidomide + rituximab in relapsed/refractory follicular lymphoma or marginal zone lymphoma
NL-OMON54337Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) comparing Tafasitamab + lenalidomide + rituximab with Placebo + lenalidomide + rituximab (2 arms). Primary endpoint: Progression-free survival by investigator assessment in the follicular lymphoma population. Started Jan 2022; status: recruiting.
02
Drugs
tafasitamablenalidomiderituximab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NL-OMON54337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54337.